Price
Target price
€2.04
€2.04
-11.450%
-0.257
-11.450%
€3.40
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cardiol Therapeutics Inc. Stock
Heavy losses for Cardiol Therapeutics Inc. today as the stock fell by -€0.257 (-11.450%).
Currently there is a rather positive sentiment for Cardiol Therapeutics Inc. with 4 Buy predictions and 1 Sell predictions.
As a result the target price of 3 € shows a positive potential of 47.42% compared to the current price of 2.04 € for Cardiol Therapeutics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Cardiol Therapeutics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Cardiol Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
- Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain
- CardiolRx™ also shown to reduce inflammation in patients
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
- Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients with recurrent pericarditis, with topline results expected in Q2 2024
-